Trial Profile
ALERT: A phase II study of alternating eribulin and hormonal therapy in pre-treated ER+ve breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ALERT
- 19 Sep 2018 Status changed from recruiting to discontinued due to slow patient recruitment.
- 14 Sep 2015 New trial record